Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Jun;8(3):1827-1839.
doi: 10.1002/ehf2.13251. Epub 2021 Mar 3.

Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score

Affiliations
Multicenter Study

Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score

Olivier Huttin et al. ESC Heart Fail. 2021 Jun.

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] ESC Heart Fail. 2021 Oct;8(5):4364. doi: 10.1002/ehf2.13551. Epub 2021 Aug 2. ESC Heart Fail. 2021. PMID: 34342175 Free PMC article. No abstract available.

Abstract

Aims: Echocardiographic predictors of outcomes in heart failure with preserved ejection fraction (HFpEF) have not been systematically or independently validated. We aimed at identifying echocardiographic predictors of cardiovascular events in a large cohort of patients with HFpEF and to validate these in an independent large cohort.

Methods and results: We assessed the association between echocardiographic parameters and cardiovascular outcomes in 515 patients with heart failure with preserved left ventricular (LV) ejection fraction (>50%) in the MEtabolic Road to DIAstolic Heart Failure (MEDIA) multicentre study. We validated out findings in 286 patients from the Karolinska-Rennes Prospective Study of HFpEF (KaRen). After multiple adjustments including N-terminal pro-brain natriuretic peptide (NT-proBNP), the significant predictors of death or cardiovascular hospitalization were pulmonary arterial systolic pressure > 40 mmHg, respiratory variation in inferior vena cava diameter > 0.5, E/e' > 9, and lateral mitral annular s' < 7 cm/s. The combination of these four variables differentiated patients with <10% vs. >35% 1 year risk. Adding these four echocardiographic variables on top of clinical variables and NT-proBNP yielded significant net reclassification improvement (33.8%, P < 0.0001) and increase in C-index (5.3%, a change from 72.2% to 77.5%, P = 0.015) of similar magnitude as the addition of NT-proBNP on top of clinical variables alone. In the KaRen cohort, these four variables yielded a similar improvement in net reclassification improvement (22.3%, P = 0.014) and C-index (4.0%, P = 0.029).

Conclusions: Use of four simple echocardiographic parameters (within the MEDIA echo score), indicative of pulmonary hypertension, elevated central venous pressure, LV diastolic dysfunction, and LV long-axis systolic dysfunction, independently predicted prognosis and improved risk stratification additionally to clinical variables and NT-proBNP in HFpEF. This finding was validated in an independent cohort.

Keywords: Cardiac oedema; Cardiovascular diseases; Diastolic function; Echocardiography; Heart failure, diastolic; Preserved ejection fraction; Risk prediction.

PubMed Disclaimer

Conflict of interest statement

L.H.L. related to present manuscript: none; unrelated: research grants to author's institution and speaker's and/or consulting fees: AstraZeneca, Boehringer Ingelheim, Novartis, Bayer, Vifor Pharma, Boston Scientific, Sanofi, Myokardia, Pharmacosmos, Mundipharma, Orion Pharma, Merck/MSD, and Medscape. N.G. reports consulting fees, unrelated to this manuscript, from AstraZeneca, Boehringer Ingelheim, and Novartis. P.R. reports personal fees from Relypsa, Inc., a Vifor Pharma Group Company; AstraZeneca; Bayer; CVRx; Fresenius; Novartis; Grunenthal; Servier; Stealth Peptides; Vifor Fresenius Medical Care Renal Pharma; Idorsia; and Novo Nordisk, outside the submitted work; and cofounder: CardioRenal. F.Z. reports personal fees from AstraZeneca, Janssen, Bayer, Novartis, Boston Scientific, Resmed, Amgen, CVRx, General Electric, Boehringer, AstraZeneca, and Vifor Fresenius, outside the submitted work, and cofounder: CardioRenal.

Figures

Figure 1
Figure 1
Associations between echocardiographic measurements and high levels of N‐terminal pro‐brain natriuretic peptide (> 450 pg/mL in patients below 50 years, >900 in patients aged 50–75 years, and >1800 in patients over 75 years). *Adjusted on age, estimated glomerular filtration rate, body mass index, atrial fibrillation, and clinical presentation.
Figure 2
Figure 2
Associations between echocardiographic parameters and time to cardiovascular/heart failure hospitalization or all‐cause death. *Adjusted for dichotomous N‐terminal pro‐brain natriuretic peptide, age, estimated glomerular filtration rate, gender, left ventricular ejection fraction, atrial fibrillation, and clinical presentation.
Figure 3
Figure 3
Multivariable integrated echocardiographic models in the MEDIA project (Panel A) and its added prognostic value in the MEDIA project (Panel B) and the KaRen cohort (Panel C). Panel A: Cox regression model using subset of variables retained after backward selection (using missing‐indicator method) with N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) as a dichotomous or linear variable; Panels B and C: Improvement in prognostic value for the primary endpoint on top of clinical model (including age, estimated glomerular filtration rate, atrial fibrillation, and heart failure status), assessed by net reclassification improvement (NRI) and C‐index.

Similar articles

Cited by

References

    1. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population‐based study. N Engl J Med 2006; 355: 260–269. - PubMed
    1. Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite‐Moreira AF, Borbély A. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539–2550. - PubMed
    1. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165–193. - PubMed
    1. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CS, Lancellotti P. How to diagnose heart failure with preserved ejection fraction: the HFA‐PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020; 22: 391–412. - PubMed
    1. Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence‐based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138: 861–870. - PMC - PubMed

Publication types